Resveratrol has 2 documented interactions in Magellan’s curated dataset, covering Statins (cholesterol medications), Immunosuppressants, Sedatives and sleep medications, PDE5 inhibitors (sildenafil, tadalafil), Calcium channel blockers, Anticoagulants (blood thinners) and others. Each entry below gives the mechanism as the cited reference states it, the direction the risk runs, how serious that reference treats it, and what to actually do about it — which is, in every case, a conversation with the clinician or pharmacist who manages the prescription rather than a decision you make alone.
What it is. Resveratrol (trans-3,5,4'-trihydroxystilbene) is a natural polyphenol produced by grapes, berries, peanuts and other plants as a defensive phytoalexin, and it is found in especially high concentration in red wine — though current health guidance that no level of alcohol consumption is safe has undercut the 'red wine' rationale that first popularized it. It acts as an antioxidant and has been reported to engage nutrient-sensing pathways associated with aging, including activation of SIRT1/sirtuins and AMP-activated protein kinase (AMPK).
Where it sits on the evidence. Magellan grades the supplement itself as Moderate evidence, with a typical studied dose of Most trials use roughly 150-1,000 mg/day; anti-inflammatory effects were strongest at 500 mg/day or more for at least 10 weeks, and the 24-month cognitive trial used 75 mg twice daily. That grade is about whether it works, not about whether it is safe alongside your medication — the two questions are independent, and this page answers only the second.
Products this covers: Purovitalis Liposomal Trans-Resveratrol.
How the risks cluster. The entries split across 2 different mechanisms — drug levels; bleeding risk — and they are not managed the same way, so read each one rather than assuming a single rule covers all of them.
Safety and efficacy are separate questions, and this page only answers the first. For the second, the study Magellan’s coverage of Resveratrol rests on is:
“Over 24 months, 75 mg twice-daily resveratrol improved overall cognitive performance by 33% versus placebo and enhanced cerebral blood flow and insulin sensitivity in postmenopausal women — a single-cohort result awaiting replication.”
A strong result does not make a supplement safe alongside your prescription, and a documented interaction does not mean the supplement does not work. Magellan grades those two things separately, and neither grade moves for a commission.
Magellan’s Medication Safety Check runs entirely on your device — type the medicines you take and it flags every documented interaction in this dataset. Nothing you type is sent anywhere.
Open the Medication Safety Check →At higher doses resveratrol can systemically inhibit cytochrome P450 enzymes, potentially attenuating or altering the activity of drugs that rely on these pathways; a 2020 literature review flags this as a real but understudied interaction risk.
Medicines in this group include: Atorvastatin (Lipitor), Simvastatin (Zocor), Rosuvastatin (Crestor), Lovastatin (Mevacor, Altoprev), Pravastatin (Pravachol), Pitavastatin (Livalo), Fluvastatin (Lescol), Cyclosporine (Neoral, Sandimmune) and 20 more.
In an animal pharmacokinetic study, resveratrol increased warfarin exposure and INR via CYP2C9/BCRP inhibition; the authors cautioned that warfarin-treated patients should be aware of a hidden bleeding risk from resveratrol supplementation. Resveratrol also has antiplatelet activity that can add to bleeding risk with blood thinners.
Medicines in this group include: Warfarin (Coumadin, Jantoven), Apixaban (Eliquis), Rivaroxaban (Xarelto), Dabigatran (Pradaxa), Edoxaban (Savaysa), Heparin (Lovenox, Enoxaparin), Acenocoumarol (Sintrom), Aspirin (Asa, Bayer aspirin) and 4 more.
These are the warning signs that go with the medication classes on this page. They are general safety-netting, not a prediction that any supplement will cause them.
If something feels seriously wrong, do not wait for an appointment. Call 911 (US) or your local emergency number.
Severity describes the interaction as the cited reference frames it, not how a specific person will react. A “minor” entry in someone with kidney disease, on five other drugs, can matter more than a “major” one in someone on nothing else.
This is a curated set of interactions with citations — not an exhaustive pharmacology database. An interaction that is absent here has not been ruled out; it may simply not be documented in the references Magellan curates from. Supplements are also not batch-tested for identity or contamination the way prescription drugs are, so what is on the label is a claim rather than a guarantee. And most of these entries come from case reports and mechanistic work rather than randomized trials, which is exactly why the sensible response is a pharmacist review rather than either alarm or dismissal.
9 documented interactions across 9 supplements.
7 documented interactions across 7 supplements.
43 documented interactions across 24 supplements.
3 documented interactions · shares a drug class with Resveratrol.
2 documented interactions · shares a drug class with Resveratrol.
3 documented interactions · shares a drug class with Resveratrol.
3 documented interactions · shares a drug class with Resveratrol.
The mechanism and the research behind the compound itself.
A–Z of every supplement and drug class in this dataset, plus how to read an interaction.
What the research actually shows, graded independently of affiliate commissions.
Not without checking with the prescriber or pharmacist first. Magellan's dataset grades this as a moderate interaction: At higher doses resveratrol can systemically inhibit cytochrome P450 enzymes, potentially attenuating or altering the activity of drugs that rely on these pathways; a 2020 literature review flags this as a real but understudied interaction risk. (Source: Potential Adverse Effects of Resveratrol: A Literature Review.)
2 interactions are documented in Magellan's curated dataset: 2 moderate. They cover Statins (cholesterol medications), Immunosuppressants, Sedatives and sleep medications, PDE5 inhibitors (sildenafil, tadalafil), Calcium channel blockers. Absence from this list is not proof of safety — it means no interaction is documented in the references we curate from.
Magellan lists the typical studied dose as: Most trials use roughly 150-1,000 mg/day; anti-inflammatory effects were strongest at 500 mg/day or more for at least 10 weeks, and the 24-month cognitive trial used 75 mg twice daily. Dose matters for interactions — several of the entries on this page describe effects that only appear at supplemental rather than dietary intakes.